Transcenta Holding
Chemicals & Related Products · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3 Independence Way Ste 114, Princeton, N...Phone Number
+86 57128279502Website
www.transcenta.comRevenue
$28.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Transcenta Holding
Transcenta Holding is a global fully integrated biotherapeutics company that specializes in developing innovative biologics, including antibodies targeting Claudin 18.2. The company employs cutting-edge technology to create differentiated and affordable treatments for patients, with a focus on oncology. With a robust pipeline of products, including Osemitamab (TST001), TST002, and TST003, Transcenta is committed to advancing clinical development and manufacturing processes. Their strategic partnerships with leading pharmaceutical companies enhance their capabilities in research and development, ensuring a strong presence in the biopharmaceutical industry.Explore more
Transcenta Holding Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Transcenta Holding your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Transcenta Holding is spiking on competitors!
Transcenta Holding, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Transcenta Holding has recently received funding, and reach out quickly before it becomes old news!
Click to see if Transcenta Holding had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Transcenta Holding
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Transcenta Holding recently announced quarterly report
Funding: Get notified immidiatlly once Transcenta Holding has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Transcenta Holding launches new products
Recommended Actions
Find VP level buyers at Transcenta Holding
Find 2 more new buyers
Compare Similar Companies to Transcenta Holding
Compare insights from companies similar to Transcenta Holding, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Transcenta Holding
$28.2M
201-500
Private
$105M
2019
CG
Caroline GermaExecutive Vice President & Global Chief Medical Officer, Medicine Development
$17.3M
51-200
Private
$71M
2014
GR
Guy RachmuthSenior Vice President, Global Head of Strategic BD and Partnerships. Chief Business Officer
Company Profile Activity
Activity Insights
Transcenta Holding is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Transcenta Holding is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Transcenta Holding.
Transcenta Holding financials insights
Gather financial insights about Transcenta Holding, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$105M
Transcenta Holding Tech Stack
A closer look at the technologies used by Transcenta Holding
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Transcenta Holding News & Media
Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
PRINCETON, N.J. and SUZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr. Christopher Hwang as Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing (HiCB) platform, leading execution of the Transcenta’s global technology out-licTranscenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
PRINCETON, N.J. and SUZHOU, China, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced that members of its senior leadership team will participate in the 36th Annual Oppenheimer Healthcare Life Sciences Conference February 25-26, 2026.Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development andTranscenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Transcenta Holding
Sign Up For FreeTo access detailed company insights
Transcenta Holding is a global fully integrated biotherapeutics company that specializes in developing innovative biologics, including antibodies targeting Claudin 18.2. The company employs cutting-edge technology to create differentiated and affordable treatments for patients, with a focus on oncology. With a robust pipeline of products, including... Read More
